Bexxar iodine-131 radiolabeled monoclonal antibody targeted to the CD20 antigen on B cells data

CLTR announced preliminary findings with Bexxar, showing >50 percent shrinkage of tumor in all treated patients. As reported

Read the full 186 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE